Related Experiment Video
Updated: Jun 7, 2026
06:55
Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
Published on: October 26, 2016
Drug eluting coronary artery stents.
Rajashree Hirlekar1, Mayank Patel, Sunilkumar Jain
1Bharati Vidyapeeth's College of Pharmacy, Sector 8, C.B.D., Belapur, Navi Mumbai 400614, Maharashtra, India. rshirlekar@rediffmail.com
Current Drug Delivery
|October 27, 2010
Summary
Drug-eluting stents (DES) reduce restenosis after coronary angioplasty by releasing drugs from polymer coatings. Bioabsorbable stents are emerging as a promising alternative to polymer-coated DES.
Area of Science:
- Cardiovascular Medicine
- Biomaterials Science
- Interventional Cardiology
Background:
- Atherosclerosis causes coronary heart disease, leading to arterial stenosis.
- Bare metal stents used in Percutaneous Transluminal Coronary Angioplasty (PTCA) have high rates of restenosis.
- Drug-eluting stents (DES) were developed to address restenosis by eluting drugs from polymer coatings.
Purpose of the Study:
- To review the current landscape of Drug-Eluting Stents (DES).
- To discuss the mechanisms and applications of drug elution from stents.
- To explore the future prospects of DES, including bioabsorbable stent technology.
Main Methods:
- Review of literature on Drug-Eluting Stents (DES) and coronary angioplasty.
- Analysis of drug elution mechanisms (diffusion, dissolution, ion exchange).
- Discussion of stent coating techniques (dip coating, spray coating, ink-jet coating).
Main Results:
- DES utilize polymer coatings as drug reservoirs to prevent restenosis.
- Coated stents release various drugs (immunosuppressants, anti-neoplastics, etc.) to inhibit thrombus formation, inflammation, and cellular proliferation.
- Bioabsorbable stents are emerging as a potential successor to polymer-coated DES.
Conclusions:
- Drug-eluting stents are effective in reducing restenosis following coronary angioplasty.
- Advancements in coating technologies and drug delivery mechanisms enhance DES efficacy.
- Bioabsorbable stents represent the next frontier in coronary stent technology, offering potential advantages over current DES.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Cardiac Catheterization I: Pre-Procedure Overview
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...